RNAi Technology Market

Market Outlook

The global RNAi technology market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.8 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 14.0% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of molecule, siRNA holds the highest share of the current market.
• With respect to delivery technology, lipid nanoparticles dominate (nearly 55%) the current market.
• Based on the application area, the therapeutics segment captures the largest share of the current market.
• Amongst the end users, pharmaceutical and biotechnology companies capture majority (close to 60%) of the current market.
• In terms of geographical regions, North America currently holds the highest market share (nearly 40%).

Key Market Statistics

• Market Size in 2026: $3.8 Billion
• Estimated Market Size in 2035: $12.5 Billion
• CAGR (2026-2035): 14.0%
• North America: Largest market in 2026
• Asia-Pacific: Fastest-growing region

Market Introduction

RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses disease-causing genes at the messenger RNA (mRNA) level. Initially developed as a research tool, RNAi has evolved into a clinically validated therapeutic platform. The commercial success of RNAi medicines such as Onpattro and Amvuttra has demonstrated its potential to treat genetic and metabolic disorders through highly targeted mechanisms.

The RNAi field is rapidly expanding beyond rare diseases into broader therapeutic areas. A notable example is zilebesiran, an investigational RNAi therapy being developed by Alnylam Pharmaceuticals and Roche for uncontrolled hypertension. Its progression into Phase III clinical development highlights growing confidence in RNAi's ability to provide long-lasting treatment benefits for large patient populations.

Recent innovations in delivery technologies are further accelerating RNAi adoption. Advances in lipid nanoparticles (LNPs), GalNAc conjugates, and other targeted drug delivery platforms have improved tissue-specific delivery and therapeutic efficacy. In parallel, artificial intelligence is increasingly being utilized to optimize siRNA design and candidate selection, helping reduce development timelines and improve the success rate of RNAi drug discovery programs.

Beyond healthcare, RNAi technology is gaining momentum in agriculture and industrial biotechnology. RNA-based crop protection solutions are being developed to improve disease resistance, enhance productivity, and reduce dependence on conventional pesticides. These advancements are expanding the commercial applications of RNAi and positioning technology as a key enabler of innovation across both life sciences and sustainable agriculture sectors.

Top Companies Operating in RNAi Technology Market

Market Segmentation

Based on the research, we have segmented the RNAi Technology Market into type of molecule, delivery technology, application area, end user and geographical regions.

By Type of Molecule

• miRNA
• shRNA
• siRNA
• Other RNA Molecules

By Delivery Technology

• Lipid Nanoparticles
• Polymer and Conjugate Systems
• Emerging Nanomaterials
• Viral Vectors

By Application Area

• Agriculture
• Diagnostics
• Drug Discovery and Screening
• Therapeutics
• Other Application Areas

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Development and Manufacturing Organizations
• Diagnostic Laboratories
• Other End Users

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

RNAi Technology Market Key Insights

What are the Key Drivers for RNAi Technology Market Growth?

• Advancements in Delivery Technologies: Advances in delivery systems, such as GalNAc conjugates and lipid nanoparticles, have improved stability, cellular uptake, and targeted delivery of RNAi molecules, overcoming earlier barriers and expanding therapeutic applications. For instance, Alnylam's proprietary platforms like GalNAc (N-acetylgalactosamine) conjugates have enabled multiple approvals, facilitating broader clinical use.
• Expanding Clinical Success of RNAi Therapeutics: The increasing regulatory approvals and late-stage clinical progress of RNAi therapeutics are validating the technology as a mainstream treatment modality. For instance, Amvuttra received FDA approval for transthyretin amyloid cardiomyopathy, making it the first available treatment for both nerve and heart manifestations of ATTR amyloidosis.

What are the Main Challenges for Market Growth?

• Delivery and Stability Issues: Efficient, safe delivery to target tissues beyond the liver remains a major hurdle due to degradation, poor uptake, and immunogenicity of RNAi molecules. This limits broader applications, with most development programs facing delivery-related challenges, as noted in industry analyses.
• High Manufacturing Complexity and Commercialization Costs: RNAi therapeutics require sophisticated oligonucleotide synthesis, formulation technologies, and stringent quality controls. This results in high production costs and significant capital investment for commercial-scale manufacturing.

Recent Developments in RNAi Technology Market

• In June 2026, Alnylam Pharmaceuticals entered into a collaboration with Inceptive Nucleics valued at USD 2 billion. The partnership aims to integrate Inceptive's AI-driven foundation models with Alnylam's RNAi platform to accelerate siRNA drug discovery, optimize molecule design, and improve efficiency across preclinical, regulatory, and commercial stages.
• In June 2026, AviadoBio, a gene therapy company focused on neurodegenerative disorders, and King's College London announced an expansion of a license agreement. The deal grants AviadoBio worldwide rights to utilize its proprietary vMiX™ RNAi gene silencing platform across all human therapeutic areas.
• In February 2026, SanegeneBio signed a global licensing agreement with Genentech. Under the deal, SanegeneBio granted Genentech exclusive worldwide rights to develop and commercialize one of its RNAi programs leveraging SanegeneBio's proprietary platform.

Industry Experts on RNAi Technology Market

Driven by major pharmaceutical partnerships, alongside advances in extra-hepatic delivery technologies, the RNAi technology market is expected to grow in the near future.

Emphasizing this shift, William Soliman (Founder and Chief Executive Officer, Accreditation Council for Medical Affairs), in an interview with Drug Discovery News, stated, "Whoever cracks heart, lung, kidney, CNS delivery with the same precision GalNAc gave the liver will control the next wave of billion-dollar assets."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the third-party discussions:

• Founder and Chief Executive Officer, Mid-sized Company, US
• President and Chief Executive Officer, Mid-sized Company, UK
• President and Chief Executive Officer, Small Company, US
• Chief Executive Officer and Co-Founder, Small Company, US
• Chief Executive Officer, Large Company, US
• Senior Vice President, Head of International Region, Large Company, US
• Executive Vice President, Chief Commercial Officer, Large Company, US
• Chief Technology Officer and Head of US Operations, Mid-sized Company, US
• Former Chief Medical Officer, Large Company, US
• Head of Advanced Drug Delivery, Very Large Company, UK

Market Share Insights

Which Type of Molecule Accounts for the Largest Share in the RNAi Technology Market?

This segment highlights the distribution of market value for RNAi technology across various types of molecules, such as miRNA, shRNA, siRNA and other RNA molecules.

Currently, the siRNA segment captures the majority of the RNAi technology market share. The dominance of siRNA stems from its robust clinical and commercial validation across approved RNAi drugs and late-stage pipeline candidates. siRNA platforms leverage proven gene-silencing mechanisms, refined chemical modification approaches, and increasing adoption of targeted delivery, especially conjugate-based systems. Recently, in January 2026, researchers at the University of North Carolina at Chapel Hill have developed a new platform technology to enhance the overall RNA interference (RNAi) potency. As pharma and biotech firms progress siRNA programs for genetic, metabolic, cardiovascular, and other indications, this segment is likely to retain its market-leading position.

In contrast, the shRNA segment is expected to register the highest CAGR during the forecast period. This accelerated growth is due to the vector-based delivery that enables more persistent gene silencing, making shRNA particularly suited to indications that require sustained therapeutic activity. Increasingly, developers are exploring shRNA approaches for complex and chronic diseases where durable target suppression could provide clinical benefits. As vector design, delivery methods, and gene therapy manufacturing advance, shRNA platforms are poised to capture greater share of the RNAi technology market.

Market Share by Delivery Technology: Lipid Nanoparticles Segment to Hold the Highest Market Share

Based on the delivery technology, the global market is segmented into emerging nanomaterials, lipid nanoparticles, polymer and conjugate systems, and viral vectors.

Currently, the lipid nanoparticles sub-segment is likely to capture the majority (~55%) of the RNAi technology market size. This is due to the fact that lipid nanoparticles represent the most clinically validated and commercially scalable non-viral delivery platforms. Moreover, they offer well-established manufacturing processes, regulatory familiarity, and proven success in approved siRNA therapeutics. In addition, their ability to efficiently encapsulate and protect RNA molecules while enabling targeted delivery to the liver has made them the preferred choice for late-stage clinical programs and commercial products.

Further, it is worth highlighting that, as per the RNAi technology market analysis, the emerging nanomaterial sub-segment is likely to grow at a relatively higher CAGR during the forecast period. This is due to the industry's shift toward overcoming the limitations of conventional LNPs, particularly for extrahepatic delivery, repeat dosing, and cell-specific targeting. Novel carriers including polymeric, inorganic, biomimetic, peptide-based, and extracellular vesicle-inspired nanoparticles are being engineered to enhance biodistribution, reduce immunogenicity, and enable delivery to difficult-to-reach tissues.

Which Application Area Holds the Largest Share in the Market?

Based on the application area, the global market is segmented into agriculture, diagnostics, drug discovery and screening, therapeutics, and other application areas.

According to our market analysis, therapeutics occupies the highest market share in the RNAi technology market. This trend stems from its relatively advanced commercialization pathway, supported by multiple regulatory approvals, expanding clinical pipelines, and growing investments in precision medicine. The approvals of RNAi therapeutics such as patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran have validated RNAi as a commercially viable modality and stimulated further investment in associated technology platforms. Consequently, pharmaceutical companies are increasingly deploying RNAi platforms to liver, cardiovascular, metabolic, and rare genetic indications, where targeted gene silencing can deliver differentiated clinical benefits.

On the contrary, the agriculture segment is likely to grow at a higher CAGR during the forecast period. This stems from the transition of RNAi-based crop protection solutions from research to commercial deployment, which is driven by the need for sustainable pest management, resistance mitigation, and reduced dependence on conventional chemical pesticides. For instance, RNAi-based approaches are increasingly being replaced by species-specific gene silencing. Moreover, regulatory acceptance of spray-induced gene silencing (SIGS) technologies and increasing investments from agrochemical and biotechnology companies are accelerating product development across high-value crops.

Which End User Captures the Highest Share of RNAi Technology Market?

On the basis of end user, the global market is distributed into academic and research institutes, contract development and manufacturing organizations, diagnostic laboratories, pharmaceutical and biotechnology companies, and other end users.

Currently, pharmaceutical and biotechnology companies occupy the highest (around 60%) share in the overall market. This is due to the fact that these companies increasingly internalize RNAi discovery and clinical development to retain control over high-value intellectual property, platform optimization, and long-term product pipelines. Rather than relying solely on outsourced capabilities, leading developers are expanding in-house expertise in RNA design, delivery technologies, and translational research to accelerate first-in-class and follow-on therapeutic programs. Moreover, these companies possess the financial resources, technical expertise, and clinical development infrastructure required to advance RNAi platforms.

Additionally, it is worth highlighting that, as per RNAi technology market analysis, the market share for contract development and manufacturing organizations is likely to grow at a relatively higher CAGR during the forecast period. Rising outsourcing of RNAi development, formulation, analytical testing, and manufacturing by therapy developers is driving this demand. As RNAi programs grow in complexity and require specialized capabilities in oligonucleotide synthesis, delivery formulation, and stringent quality control, CDMOs are set to become increasingly critical partners in advancing RNAi therapeutics and associated technologies.

Regional Analysis: Which Regions are Showing the Fastest Growth in RNAi Technology Industry?

North America Market: Securing the Highest Share

In terms of geographical regions, the global market is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.

According to our RNAi technology market forecast, North America is likely to capture the majority (around 40%) of the RNAi technology market share in the current year, and this trend is unlikely to change. The region's dominance is owing to its mature commercialization ecosystem, characterized by the presence of leading RNAi innovators, strong venture and public funding, advanced genomic research infrastructure, and an established regulatory pathway for nucleic acid therapeutics. Moreover, companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals reinforce North America's position through active pipeline development, strategic technology partnerships, and ongoing investment in next–generation RNAi platforms.

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is likely to grow at a high CAGR during the forecast period till 2035. This is primarily due to rapidly expanding biotechnology capabilities, increasing government investments in genomic medicine, a growing clinical trial landscape, and the emergence of cost-efficient RNA manufacturing and development hubs in the region. Moreover, countries such as China, Japan, South Korea, and Singapore are increasingly positioning themselves as key centers for RNA-based therapeutic innovation and commercialization, driving the growth of the market. For instance, China's ICAMA has drafted streamlined data requirements for RNA pesticides and has begun reviewing first-generation RNAi biopesticides (specifically double-stranded RNA targeted to suppress the Tobacco Mosaic Virus).

Scope of RNAi Technology Market Report